
PRVB
Healthcare · Biotechnology · $2.38B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2023
EPS trend, 90 days to now · -175.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 29, 2023 | After the close | -0.46 | -0.45 | +2.2% |
| Nov 3, 2022 | Before the open | -0.42 | -0.34 | +19.0% |
| Aug 4, 2022 | Before the open | -0.50 | -0.46 | +8.0% |
| May 5, 2022 | Before the open | -0.47 | -0.35 | +25.5% |
| Feb 24, 2022 | Before the open | -0.45 | -0.41 | +8.9% |
| Nov 4, 2021 | Before the open | -0.51 | -0.43 | +15.7% |
| Aug 5, 2021 | Before the open | -0.52 | -0.46 | +11.5% |
| May 6, 2021 | Before the open | -0.46 | -0.52 | -13.0% |
| Feb 25, 2021 | Before the open | -0.50 | -0.58 | -16.0% |
| Nov 5, 2020 | Before the open | -0.43 | -0.56 | -30.2% |
| Aug 6, 2020 | Before the open | -0.28 | -0.45 | -60.7% |
| May 7, 2020 | After the close | -0.25 | -0.26 | -4.0% |
| Mar 12, 2020 | Before the open | -0.24 | -0.22 |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial…
| +8.3% |
| Nov 5, 2019 | After the close | -0.29 | -0.24 | +17.2% |
| Aug 6, 2019 | Before the open | -0.31 | -0.32 | -3.2% |
| May 8, 2019 | After the close | -0.18 | -0.29 | -61.1% |
| Mar 19, 2019 | After the close | -0.19 | -0.15 | +21.1% |
| Nov 8, 2018 | Before the open | -0.19 | -0.20 | -5.3% |
| Jul 3, 2018 | After the close | 0.00 | -0.11 | — |
| Feb 12, 2018 | Time not confirmed | — | -0.17 | — |